UCLA study overturns dogma of cancer metabolism theory
(University of California - Los Angeles Health Sciences) Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered that squamous cell skin cancers do not require increased glucose to power their development and growth, contrary to a long-held belief about cancer metabolism. The findings could bring about a better understanding of many cancers' metabolic needs and lead to the development of more effective therapies for squamous cell skin cancer and other forms of epithelial cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2019 Category: Cancer & Oncology Source Type: news
Photosensitizing Antihypertensive Drug Use and Risk of cSCC Photosensitizing Antihypertensive Drug Use and Risk of cSCC
Might treatment with photosensitizing antihypertensive drugs increase the risk of developing cutaneous squamous cell carcinoma?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Pembrolizumab Shows Modest Activity in Advanced Esophageal Cancer Pembrolizumab Shows Modest Activity in Advanced Esophageal Cancer
Pembrolizumab benefits a minority of heavily pretreated patients with advanced metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, according to an open-label phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Skin Cancer | Medscape Skin Cancer | Medscape
Nonmelanoma skin cancer primarily comprises basal cell carcinoma and squamous cell carcinoma. Other, rarer types of nonmelanoma skin cancer include dermatofibrosarcoma protuberans, Merkel cell carcinoma, and Kaposi ' s sarcoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news
Bladder Cancer | Medscape Bladder Cancer | Medscape
Bladder cancer is the second most common urologic malignancy. Transitional cell carcinoma accounts for more than 90% of cases; other types include squamous cell carcinoma and adenocarcinoma. In stage 1 disease, when the tumors are superficial, bladder cancer is treatable with transurethral resection and intravesical therapy. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news
Pembrolizumab Promising for Metastatic Head, Neck SCC
Prolongs survival among patients with recurrent, metastatic head and neck squamous cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 20, 2018 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Journal, Source Type: news
Pembrolizumab Promising for Metastatic Head, Neck SCC
THURSDAY, Dec. 20, 2018 -- For patients with recurrent or metastatic head and neck squamous cell carcinoma, pembrolizumab has a favorable safety profile and is associated with prolongation of overall survival, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2018 Category: Pharmaceuticals Source Type: news
TRIM29: A New Target in Treatment of Squamous Cell Carcinoma?
A new study inCancer Research evaluated the function of TRIM29 in regulating keratin distribution and migration/invasion of SCC. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
CNIO and Hospital 12 de Octubre extend effectiveness of immunotherapy to more lung cancer patients
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients.Squamous cell carcinoma represents 20 percent to 30 percent of all cases of lung cancer and has a worse prognosis than other variants. It has the least amount of progress in terms of treatment.Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2018 Category: International Medicine & Public Health Source Type: news
How Useful Are Immune Checkpoint Markers in Squamous Cell Carcinoma?
A recent study examined the literature on whether immune checkpoint molecules improve overall survival in oral squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 29, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Skin cancer rates far higher than previously thought, according to new national database
(Queen Mary University of London) Data from a newly established UK skin cancer database, the largest of its kind in the world, has revealed that there are over 45,000 cutaneous squamous cell carcinomas every year in England, 350 percent more than previous estimates suggested. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 28, 2018 Category: International Medicine & Public Health Source Type: news
Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
HPV blood test shows promise for tracking head and neck cancer after treatment
(UNC Lineberger Comprehensive Cancer Center) Researchers will present preliminary findings at the 60th Annual Meeting of the American Society for Radiation Oncology in San Antonio on Tuesday, Oct. 23, from a study that evaluated a blood test for HPV-linked oropharyngeal squamous cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2018 Category: Cancer & Oncology Source Type: news
Biomarker blood test confirms remission in patients with HPV+ oral cancer
(American Society for Radiation Oncology) A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2018 Category: Cancer & Oncology Source Type: news
NUS researchers elucidate roles TP63 and SOX2 in squamous cell cancer progression
(National University of Singapore) Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have identified a SCC-specific protein complex activated by TP63 and SOX2 which triggers a gene cascade that promotes SCC growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 14, 2018 Category: Cancer & Oncology Source Type: news
